Asian Pacific Journal of Cancer Prevention

  • 제13권1호
  • /
  • Pages.301-304
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Clinical Application of Serum Tumor Associated Material (TAM) from Non-small Cell Lung Cancer Patients

  • Li, Cheng-Guang (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) ;
  • Xu, Lin (Department of Thoracic Surgery, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) ;
  • Li, Ying (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University) ;
  • Lu, Yan-Yan (Department of Chemotherapy, The Affiliated JiangSu Cancer Hospital of Nanjing Medical University)
  • 발행 : 2012.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To explore the associations of serum tumor associated material (TAM) with other common tumor markers like carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen19-9 (CA19-9) and its clinical application in non-small cell lung cancer (NSCLC) patients. Methods: A total of 87 patients were enrolled into this study, all with histologically or cytologically confirmed NSCLC. With the method of chemical colorimetry, the level of TAM was determined and compared, while chemiluminescence was used to measure the levels of common tumor markers. Results: The level of TAM decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. Furthermore, it increased when disease progessed and there was no statistically significant difference in monitoring of TAM and common tumor markers (P>0.05). Conclusions: Detecting TAM in NSCLC patients has a higher sensitivity and specificity, so it can be used as an indicator for clinical monitoring of lung cancer chemotherapy.

키워드

참고문헌

  1. Basu PS, Majhi R, Batabyal SK (2003). Lectin and serum-PSA interaction as a screeninng test for prostate cancer. Clin Biochem, 36, 373-6. https://doi.org/10.1016/S0009-9120(03)00050-X
  2. Dennis JW, Laferte S, Waghorne C, et al (1987). $\beta$1-6 branching of asn-linked oligosaccharides is directly associated with metastasis. Science, 236, 582-5. https://doi.org/10.1126/science.2953071
  3. Deng H, Zhong BY, Peng GH, et al (2010). Application of Bo Xin SerumTumor Associated Material ( BXTM) in Malignant Tumor. Prac Prev Med, 17, 2493-5.
  4. Diez M, Torres A, Maestro ML, et al (1996). Prediction of survival and recurrence by serum and cytosolic level sof CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer, 73, 1248-54. https://doi.org/10.1038/bjc.1996.239
  5. Foa P, Fornier M, Miceli R, et al (1999). Tumour markers CEA, NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lungcancer. Anticancer Res, 19, 3613-8.
  6. Gabius HJ (1988). Tumor lectinology- at the intersection of carbohydrate chemistry, biochemistry, cell biology, and oncology. Angew Chem, 27, 1267-76. https://doi.org/10.1002/anie.198812671
  7. Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81. https://doi.org/10.1093/jnci/92.3.179
  8. Hakomori S (2000). Traveling for the glycosphingolipid path. Glycoconj J, 17, 627-47. https://doi.org/10.1023/A:1011086929064
  9. Hakomori S, Zhang Y (1997). Glycosphingolipid antigens and cancer therapy. Chem Biol, 4, 97-104. https://doi.org/10.1016/S1074-5521(97)90253-2
  10. Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer, 4, 45-60. https://doi.org/10.1038/nrc1251
  11. Jiang M, Pu R (2010). Study on serum tumor related material (BXTM) with early diagnosis in malignant tumor. National Medical Frontiers of China, 5, 80-1.
  12. Kim YJ, Varki A (1997). Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J, 14, 569-76. https://doi.org/10.1023/A:1018580324971
  13. Kui Wong N, Easton RL, Panico M, et al (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem, 278, 28619-34. https://doi.org/10.1074/jbc.M302741200
  14. Liu ZM, et al (1986). Serum free proline and free hydroxyproline and its peptide-binding determination of hydroxyproline in the evaluation of bone tumors. Chinese J Laboratory Med, 9, 129-33 (Chinese).
  15. MacDonald JS (1999). Carcinoembryonic antigen screening: Pros and cons. Sem Oncol, 26, 556-60.
  16. Matsushita Y, Cleary KR, Ota DM, et al(1990).Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal-cancer metastases. Lab Invest,63, 780-91.
  17. Meezan E, Wu HC, Black PH, et al (1969). Comparative studies on carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry, 8, 2518-24. https://doi.org/10.1021/bi00834a039
  18. Orntoft TF, Vestergaard EM (1999). Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis, 20, 362-71. https://doi.org/10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.0.CO;2-V
  19. Pancino G, Osinaga E, Charpin C, et al (1991). Purification and characterization of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Brit J Cancer, 63, 390-8. https://doi.org/10.1038/bjc.1991.91
  20. Peracaula R, Tabarés G, Royle L, et al (2003). Altered glycosylation pattern allows the distinction between prostatespecifc antigen (PSA) from normal and tumor origins. Glycobiology, 13, 457-70. https://doi.org/10.1093/glycob/cwg041
  21. Saussez S, Marchant H, Nagy N, et al (1998). Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer, 82, 252-60. https://doi.org/10.1002/(SICI)1097-0142(19980115)82:2<252::AID-CNCR2>3.0.CO;2-T
  22. Sell S (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Path, 21, 1003-19. https://doi.org/10.1016/0046-8177(90)90250-9
  23. Serum tumor associated material (TAM) testing kit, QINGDAO BO-XING Biotechnology Co., Ltd. http://www.cqtrueway.com.
  24. Shriver Z, Raguram S, Sasisekharan R (2004). Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Disc, 3, 863-73. https://doi.org/10.1038/nrd1521
  25. Taylor-Papadimitriou J, Epenetos AA (1994). Exploiting altered glycosylation patterns in cancer- progress and challenges in diagnosis and therapy. Trends Biotech, 12, 227-33. https://doi.org/10.1016/0167-7799(94)90121-X
  26. Turner GA (1992). N-Glycosylation of serum-proteins in disease and its investigation using lectins. Clin Chim Acta, 208, 149-71. https://doi.org/10.1016/0009-8981(92)90073-Y
  27. Vinolas N, GalanMC, Casas F, et al (1998). Tumor markers inresponse monitoring and prognosis of non small cell lungcancer. Preliminaryreport Anticancer Res, 18, 631-4.
  28. Wu HX, et al (1983). Encyclopedia of Chinese Medical Oncology. Shanghai Science and Technology Press, 63 (Chinese).
  29. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  30. Zhang S, Cordon-Cardo C, Zhang HS, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: I.Focus on gangliosides. Int J Cancer, 73, 42-9. https://doi.org/10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
  31. Zhang S, Zhang HS, Cordon-Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer, 73, 50-6. https://doi.org/10.1002/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0
  32. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  33. Zou X, Zhang XS, Sui L, et al (2004). Role of tulnor associated material (BXTM) in early diagnosing malignant tumor. Qilu J Med Laboratory Sci, 15, 4-6.

피인용 문헌

  1. A Phase II Study on Continuous Infusional Paclitaxel and 5-Fu as First-line Chemotherapy for Patients with Advanced Esophageal Cancer vol.13, pp.11, 2012, https://doi.org/10.7314/APJCP.2012.13.11.5587
  2. Comparative Study on Transcatheter Arterial Chemoembolization, Portal Vein Embolization and High Intensity Focused Ultrasound Sequential Therapy for Patients vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6257
  3. ) Combined with Three-dimensional Conformal External Beam Radiotherapy in Treating Patients with Inoperable Esophageal Cancer vol.13, pp.12, 2012, https://doi.org/10.7314/APJCP.2012.13.12.6523
  4. Effect of Portal Vein Chemotherapy on Liver Metastasis after Surgical Resection of Colorectal Cancer vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4699
  5. Impact of Low Versus Conventional Doses of Chemotherapy During Transcatheter Arterial Chemo-embolization on Serum Fibrosis Indicators and Survival of Liver Cancer Patients vol.13, pp.9, 2012, https://doi.org/10.7314/APJCP.2012.13.9.4757
  6. Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5699
  7. Clinical Observation and Prognostic Analysis of Pemetrexed plus Platinum as First-line Treatment in Patients with Advanced Non-small Cell Lung Cancer vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6267
  8. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6403
  9. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6487
  10. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013, https://doi.org/10.7314/APJCP.2013.14.11.6663
  11. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7613
  12. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1703
  13. Potential Predictors of Sensitivity to Pemetrexed as First-line Chemotherapy for Patients with Advanced Non-Squamous NSCLCs vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2005
  14. (Javanica oil emulsion injection) Combined with Chemotherapy for Patients with Gastric Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2009
  15. Phase II Study of Pemetrexed as Second or Third Line Combined Chemotherapy in Patients with Colorectal Cancer vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2019
  16. ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2591
  17. Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2611
  18. Chemotherapy and Late Course Three Dimensional Conformal Radiotherapy for Treatment of Patients with Stage III Non-small Cell Lung Cancer vol.14, pp.4, 2013, https://doi.org/10.7314/APJCP.2013.14.4.2663
  19. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.2703
  20. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3747
  21. Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Non-small Cell Lung Cancer Before and after Intervention vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3851
  22. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3855
  23. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3871
  24. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4447
  25. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4791
  26. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  27. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013, https://doi.org/10.7314/APJCP.2013.14.9.5441
  28. Decreased levels of serum cytokeratin 19 fragment CYFRA 21-1 predict objective response to chemotherapy in patients with non-small cell lung cancer vol.6, pp.2, 2013, https://doi.org/10.3892/etm.2013.1171
  29. Clinical Study on Safety of Cantharidin Sodium and Shenmai Injection Combined with Chemotherapy in Treating Patients with Breast Cancer Postoperatively vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5597
  30. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  31. Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3451
  32. Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2987